论文部分内容阅读
目的:分析舌下特异性免疫治疗变应性鼻炎(AR)临床疗效及其影响因素。方法:以我院2012年1月~2014年1月诊治的100例变应性鼻炎患者为研究对象,均接受舌下特异性免疫治疗,以治疗2年为研究终点,比较治疗前、治疗2年后症状及体征评分、视觉模拟量表(VAS)评分及生活质量变化,评价治疗2年疗效及不良反应,同时对可能影响舌下特异性免疫治疗2年疗效的相关因素行多元线性回归分析。结果:治疗2年总有效率高达72.00%;与治疗前比较,治疗2年后症状及体征积分、VAS评分、鼻结膜炎生存质量调查问卷(RQLQ)中文版各项评分均显著下降,差异有统计学意义(P<0.05)。多元线性回归分析显示舌下特异性免疫治疗AR 2年疗效的影响因素为病程、治疗前VAS评分及患者用药依从性。结论:舌下特异性免疫治疗AR疗效明确,不良反应少,能有效缓解患者症状及体征,改善其生活质量。同时其疗效与AR患者病程长、治疗前VAS评分高、用药依从性差有关。
Objective: To analyze the clinical efficacy and influencing factors of sublingual immunotherapy of allergic rhinitis (AR). Methods: 100 patients with allergic rhinitis diagnosed and treated in our hospital from January 2012 to January 2014 were selected to receive sublingual immunotherapy, with 2 years of treatment as the study endpoint. Before treatment, treatment 2 Years after the symptoms and signs score, visual analog scale (VAS) score and quality of life changes, evaluate the efficacy of 2-year treatment and adverse reactions, while may affect the sublingual immunosuppression 2-year efficacy of the relevant factors of multiple linear regression analysis . Results: The total effective rate was as high as 72.00% after 2 years of treatment. Compared with before treatment, all the scores of symptom and symptom score, VAS score and RQLQ in Chinese version were significantly decreased after 2 years of treatment, Statistical significance (P <0.05). Multivariate linear regression analysis showed that the influencing factors of 2 year efficacy of sublingual immunotherapy on AR were course of disease, pre-treatment VAS score and medication compliance. Conclusion: Sublingual immunotherapy is effective in treating acute AR and has fewer side effects. It can effectively relieve symptoms and signs of patients and improve their quality of life. At the same time its efficacy and AR patients with longer duration, VAS score before treatment, medication compliance is poor.